SpyGlass Pharma, Inc.
About SpyGlass Pharma, Inc.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$39.9M
- Total assets
- $115.9M
- Market cap
- $627.9M
Source: SEC EDGAR · updated Jun 7, 2026
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $627.9M
- Dividend yield
- 1.39%
- Shares outstanding
- 33.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 6, 2026
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $39.9M.
- Trading 37% below its 52-week high.
- Pays a dividend yielding about 1.39% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SpyGlass Pharma, Inc..
